ALK-Abelló A/S (ALK) is a Danish pharmaceutical company specializing in allergy immunotherapy. Headquartered in Hørsholm, Denmark, the company researches, develops, and manufactures biologically derived allergen products used to prevent and treat respiratory allergies. Its portfolio spans standardized sublingual immunotherapy tablets, subcutaneous immunotherapy formulations, and diagnostic extracts, as well as an adrenaline auto-injector for the emergency treatment of anaphylaxis.
ALK’s products target common allergens such as grasses, ragweed, house dust mites, and tree pollens. The company operates under rigorous quality and regulatory standards and supplies healthcare systems internationally through direct operations and partnerships. Its activities integrate R&D, clinical development, and GMP manufacturing, with a focus on scalable biologics production and global distribution to support evidence-based allergy care.
To provide comprehensive coverage, we aggregate data and news under the name ALK, encompassing the following company names, divisions, and related entities:
ALK-Abelló.
This list encompasses current and former names, alternate names, and key divisions associated with ALK, ensuring you can easily find all relevant information under a single, unified profile.
